AstraZeneca Builds Another Respiratory Extension With Takeda Deal
This article was originally published in Scrip
AstraZeneca is to pay $575m to acquire full rights to Takeda's Daxas (roflumilast), along with other respiratory assets. The move is the latest in a series of bolt-on acquisitions by the UK firm to bulk up its position in respiratory, one of its core therapeutic franchises along with oncology and cardiovascular/metabolic.
Register for our free email digests: